Recently, a greater response rate was reported when bisphosphonates or RANKL inhibitors were combined with radiotherapy compared to single therapy with bisphosphonates or RANKL inhibitors in patients with osteolytic bone metastases from breast cancer [13]. The gene discussed is TNFSF11; the disease is breast carcinoma.